Press Releases Polaris Group

Equities

End-of-day quote Taiwan S.E. Other stock markets 13/03/2026			5-day change	1st Jan Change
24.10 ^TWD	-9.91%		-21.24%	-22.51%

03-13	Polaris Group Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI

22/12/23	Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth	GL
04/12/23	Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	AQ
04/12/23	Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	GL
30/11/23	Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study	GL
17/11/23	Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	GL
16/08/22	Polaris : Board of Directors resolved to issue employee stock options certificates	PU
16/08/22	Polaris : Announcement for appointing the Corporate Governance Officer	PU
16/08/22	Polaris : The Board resolved the consolidated financial statements for the second quarter of 2022	PU
16/08/22	Polaris : (Announcement of correction) Polaris Group will attend 2022 Cathay Biopharmaceutical Corporate DayHosted by Cathay Securities.	PU
16/08/22	Polaris : EirGenix, Inc. will attend 2022 Cathay Biopharmaceutical Corporate DayHosted by Cathay Securities.	PU
08/07/22	Polaris : Announcement of the progress of the company's committed items at the time when the stock was listed on TWSE.	PU